Uniqure's Parkinson's Gene Therapy Moves into Clinic
By Nuala Moran
Wednesday, July 31, 2013
LONDON The first patient has been treated in a Phase I trial of Uniqure BV's gene therapy for Parkinson's disease, with the company's CEO Jörn Aldag personally assisting in the surgery, in which the gene for glial cell line-derived neurotrophic factor (GDNF) was administered directly into the brain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.